Diagnostic performance of IOTA SR and O-RADS combined with CA125, HE4, and risk of malignancy algorithm to distinguish benign and malignant adnexal masses
Authors:
- 16 June 2023
- journal article
- research article
- Published by Elsevier in European Journal of Radiology
- Vol. 165, 110926
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- IOTA simple rules for discriminating between benign and malignant adnexal masses: prospective external validationUltrasound in Obstetrics & Gynecology, 2013
- Clinically oriented three‐step strategy for assessment of adnexal pathologyUltrasound in Obstetrics & Gynecology, 2012
- Evaluation of the Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Women With a Pelvic MassObstetrics & Gynecology, 2011
- Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA groupBMJ, 2010
- Current state of biomarker development for clinical application in epithelial ovarian cancerGynecologic Oncology, 2010
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massGynecologic Oncology, 2009
- The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?American Journal of Obstetrics and Gynecology, 2008
- Simple ultrasound‐based rules for the diagnosis of ovarian cancerUltrasound in Obstetrics & Gynecology, 2008
- Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian CarcinomasCancer Research, 2005
- Reactivity of a monoclonal antibody with human ovarian carcinoma.Journal of Clinical Investigation, 1981